Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Short term Debt (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Short term Debt data on record, last reported at $125545.0 in Q3 2025.

  • For Q3 2025, Short term Debt rose 6.14% year-over-year to $125545.0; the TTM value through Sep 2025 reached $125545.0, up 6.14%, while the annual FY2024 figure was $110177.0, 7.26% down from the prior year.
  • Short term Debt reached $125545.0 in Q3 2025 per GANX's latest filing, roughly flat from $126108.0 in the prior quarter.
  • Across five years, Short term Debt topped out at $126108.0 in Q2 2025 and bottomed at $44287.0 in Q1 2021.
  • Average Short term Debt over 5 years is $102318.0, with a median of $109281.0 recorded in 2023.
  • Peak YoY movement for Short term Debt: soared 358.88% in 2021, then dropped 7.26% in 2024.
  • A 5-year view of Short term Debt shows it stood at $103826.0 in 2021, then grew by 4.15% to $108135.0 in 2022, then increased by 9.86% to $118797.0 in 2023, then decreased by 7.26% to $110177.0 in 2024, then grew by 13.95% to $125545.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $125545.0 in Q3 2025, $126108.0 in Q2 2025, and $113121.0 in Q1 2025.